Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down – Here’s What Happened

Shares of Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) gapped down before the market opened on Thursday. The stock had previously closed at $9.06, but opened at $8.66. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $8.97, with a volume of 419 shares changing hands.

Analyst Ratings Changes

SGIOY has been the topic of a number of research reports. The Goldman Sachs Group upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a report on Monday, June 15th. Jefferies Financial Group upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 14th. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Trading Down 1.4%

The company has a market cap of $15.21 billion, a price-to-earnings ratio of 8.94, a PEG ratio of 3.26 and a beta of 0.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.14 and a quick ratio of 1.00. The business’s 50-day simple moving average is $9.10 and its 200-day simple moving average is $9.42.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last issued its quarterly earnings data on Monday, August 3rd. The company reported $0.36 earnings per share for the quarter, topping analysts’ consensus estimates of $0.18 by $0.18. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 46.67% and a return on equity of 16.13%. The business had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $970.69 million. Research analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 earnings per share for the current fiscal year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Osaka. Founded in 1878, the company discovers, develops, manufactures and markets prescription medicines, with a focus on infectious diseases, central nervous system disorders and other areas of unmet medical need.

Shionogi’s portfolio includes Xofluza (baloxavir marboxil), an antiviral treatment for influenza, and F. (fostemsavir), an HIV treatment marketed in certain regions. The company also develops medicines for conditions including pain, psychiatric disorders and other diseases, while pursuing research in areas such as antimicrobial resistance and novel anti-infective therapies.

Shionogi primarily serves the Japanese market and has expanded its international presence through subsidiaries, licensing arrangements and commercial partnerships in North America, Europe and other regions.